These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29271265)

  • 1. Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer's disease.
    Zhang C; Zhou Q; Wu XN; Huang YD; Zhou J; Lai Z; Wu Y; Luo HB
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):260-270. PubMed ID: 29271265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and evaluation of pyrazolopyrimidinone derivatives as novel PDE9A inhibitors for treatment of Alzheimer's disease.
    Zhang P; Jiang MY; Le ML; Zhang B; Zhou Q; Wu Y; Zhang C; Luo HB
    Bioorg Med Chem Lett; 2020 Jul; 30(14):127254. PubMed ID: 32527553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of effective phosphodiesterase 2 inhibitors with antioxidant activities for the treatment of Alzheimer's disease.
    Jiang MY; Han C; Zhang C; Zhou Q; Zhang B; Le ML; Huang MX; Wu Y; Luo HB
    Bioorg Med Chem Lett; 2021 Jun; 41():128016. PubMed ID: 33838306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
    Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB
    ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.
    Li Z; Lu X; Feng LJ; Gu Y; Li X; Wu Y; Luo HB
    Mol Biosyst; 2015 Jan; 11(1):115-25. PubMed ID: 25328054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease.
    Su T; Zhang T; Xie S; Yan J; Wu Y; Li X; Huang L; Luo HB
    Sci Rep; 2016 Feb; 6():21826. PubMed ID: 26911795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis.
    Wu Y; Wang Q; Jiang MY; Huang YY; Zhu Z; Han C; Tian YJ; Zhang B; Luo HB
    J Med Chem; 2021 Jul; 64(13):9537-9549. PubMed ID: 34142552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease.
    Hu J; Huang YD; Pan T; Zhang T; Su T; Li X; Luo HB; Huang L
    ACS Chem Neurosci; 2019 Jan; 10(1):537-551. PubMed ID: 30252439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.
    Shao YX; Huang M; Cui W; Feng LJ; Wu Y; Cai Y; Li Z; Zhu X; Liu P; Wan Y; Ke H; Luo HB
    J Med Chem; 2014 Dec; 57(24):10304-13. PubMed ID: 25432025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New multifunctional melatonin-derived benzylpyridinium bromides with potent cholinergic, antioxidant, and neuroprotective properties as innovative drugs for Alzheimer's disease.
    Luo XT; Wang CM; Liu Y; Huang ZG
    Eur J Med Chem; 2015 Oct; 103():302-11. PubMed ID: 26363866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.
    Wu Y; Zhou Q; Zhang T; Li Z; Chen YP; Zhang P; Yu YF; Geng H; Tian YJ; Zhang C; Wang Y; Chen JW; Chen Y; Luo HB
    J Med Chem; 2019 Apr; 62(8):4218-4224. PubMed ID: 30916555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of analogs of the phenylpyridazinone NPD-001 as potent trypanosomal TbrPDEB1 phosphodiesterase inhibitors and in vitro trypanocidals.
    Veerman J; van den Bergh T; Orrling KM; Jansen C; Cos P; Maes L; Chatelain E; Ioset JR; Edink EE; Tenor H; Seebeck T; de Esch I; Leurs R; Sterk GJ
    Bioorg Med Chem; 2016 Apr; 24(7):1573-81. PubMed ID: 26935942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
    Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mining ZINC Database to Discover Potential Phosphodiesterase 9 Inhibitors Using Structure-Based Drug Design Approach.
    Hassaan EA; Sigler SC; Ibrahim TM; Lee KJ; Cichon LK; Gary BD; Canzoneri JC; Piazza GA; Abadi AH
    Med Chem; 2016; 12(5):472-7. PubMed ID: 26648332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase 9: insights from protein structure and role in therapeutics.
    Singh N; Patra S
    Life Sci; 2014 Jun; 106(1-2):1-11. PubMed ID: 24746902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.
    Verhoest PR; Proulx-Lafrance C; Corman M; Chenard L; Helal CJ; Hou X; Kleiman R; Liu S; Marr E; Menniti FS; Schmidt CJ; Vanase-Frawley M; Schmidt AW; Williams RD; Nelson FR; Fonseca KR; Liras S
    J Med Chem; 2009 Dec; 52(24):7946-9. PubMed ID: 19919087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
    Kempson J; Pitts WJ; Barbosa J; Guo J; Omotoso O; Watson A; Stebbins K; Starling GC; Dodd JH; Barrish JC; Felix R; Fischer K
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1829-33. PubMed ID: 15780616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
    Song Q; Li Y; Cao Z; Liu H; Tian C; Yang Z; Qiang X; Tan Z; Deng Y
    Bioorg Med Chem; 2018 Dec; 26(23-24):6115-6127. PubMed ID: 30470598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.
    Hutson PH; Finger EN; Magliaro BC; Smith SM; Converso A; Sanderson PE; Mullins D; Hyde LA; Eschle BK; Turnbull Z; Sloan H; Guzzi M; Zhang X; Wang A; Rindgen D; Mazzola R; Vivian JA; Eddins D; Uslaner JM; Bednar R; Gambone C; Le-Mair W; Marino MJ; Sachs N; Xu G; Parmentier-Batteur S
    Neuropharmacology; 2011 Sep; 61(4):665-76. PubMed ID: 21619887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.